Cosmo: Substantial private placement with Capital Group Verified listing

Tuesday, February 3, 2026 @ 12:00 am

Cosmo completed a major private placement, selling 937,086 treasury shares to Capital Group’s SMALLCAP World Fund. This strengthens Cosmo’s financial position, diversifies its shareholder base, and provides funding to accelerate innovation in MedTech AI, dermatology, gastroenterology, and CDMO.

Key catalysts include:

1. Breezula 12-month safety & efficacy data (spring 2026)
2. Breezula parallel filing in the US and EU (H1 2026)
3. Winlevi EU commercial launch by partners (H1 2026)

Cosmo Flash Update

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

PSI launches platform to optimize trial planning and execution

PSI CRO, a Swiss-based global full-service contract research organization (CRO), today announced the launch of SYNETIC, a next-generation AI-powered semantic knowledge platform that empowers sponsors to identify optimal trial sites, minimize startup delays, and predict and eliminate non-enrolling sites.
January 29, 2026

leadXpro & Partex.AI: Collaboration to expand indications and support out-licensing of A2BR antagonist program

leadXpro AG (“leadXpro”), a Switzerland-based pharmaceutical research and development company, and Partex.AI (“Partex”), an AI-driven therapeutic asset incubator and accelerator, today announced that they have entered into a collaboration agreement focused on expanding the therapeutic potential and supporting the future out-licensing of LeadXpro’s adenosine A2B receptor (A2BR) antagonist
January 28, 2026

abc biopply collaborates with Pathways Preclinical Partners to bring organoid technology to their network

abc biopply ag and Pathways Preclinical Partners (“Path2P”) today announced a new collaboration aimed at enforcing the integration of abc biopply’s cutting-edge preclinical NAM technology 3D CoSeedis within global drug development networks in the US.
January 28, 2026

Porton publication on polymorphic crystallization kinetics study and control

January 21, 2026

ten23 health & Becton Dickinson partner on full-service wearable injector commercialization

The partnership addresses growing demand for self-administered therapies with a scalable, ready-to-use injector platform.
January 20, 2026

Cosmo: Substantial private placement with Capital Group Verified listing

Cosmo: Substantial private placement with Capital Group Verified listing

Company

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

PSI launches platform to optimize trial planning and execution

leadXpro & Partex.AI: Collaboration to expand indications and support out-licensing of A2BR antagonist program

abc biopply collaborates with Pathways Preclinical Partners to bring organoid technology to their network

Porton publication on polymorphic crystallization kinetics study and control

ten23 health & Becton Dickinson partner on full-service wearable injector commercialization